United Therapeutics Corporation $UTHR Shares Sold by Chase Investment Counsel Corp

Chase Investment Counsel Corp reduced its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 23.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,400 shares of the biotechnology company’s stock after selling 1,375 shares during the period. Chase Investment Counsel Corp’s holdings in United Therapeutics were worth $1,844,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Norges Bank purchased a new stake in shares of United Therapeutics during the second quarter worth about $136,453,000. Invesco Ltd. lifted its stake in shares of United Therapeutics by 90.2% during the second quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock worth $254,219,000 after buying an additional 419,588 shares during the period. AQR Capital Management LLC raised its stake in United Therapeutics by 40.1% in the 2nd quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock worth $362,876,000 after acquiring an additional 364,713 shares during the last quarter. Assetmark Inc. lifted its position in United Therapeutics by 38.1% during the 2nd quarter. Assetmark Inc. now owns 715,834 shares of the biotechnology company’s stock worth $205,695,000 after acquiring an additional 197,384 shares during the period. Finally, Balyasny Asset Management L.P. lifted its position in United Therapeutics by 863.9% during the 2nd quarter. Balyasny Asset Management L.P. now owns 152,727 shares of the biotechnology company’s stock worth $43,886,000 after acquiring an additional 136,883 shares during the period. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $474.65, for a total value of $10,679,625.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Paul A. Mahon sold 8,300 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $476.34, for a total value of $3,953,622.00. Following the completion of the sale, the executive vice president owned 36,781 shares of the company’s stock, valued at $17,520,261.54. This trade represents a 18.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 407,514 shares of company stock worth $197,561,190 in the last ninety days. Company insiders own 10.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Royal Bank Of Canada increased their price objective on United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a report on Thursday, October 30th. UBS Group reiterated a “buy” rating on shares of United Therapeutics in a report on Tuesday, February 17th. Wells Fargo & Company raised their price target on shares of United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 30th. HC Wainwright upped their price objective on shares of United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $575.00 price objective on shares of United Therapeutics in a research note on Wednesday, November 19th. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $509.50.

United Therapeutics Price Performance

UTHR opened at $474.52 on Tuesday. The firm has a fifty day moving average price of $484.76 and a 200 day moving average price of $442.24. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $519.99. The stock has a market cap of $20.43 billion, a P/E ratio of 17.98, a P/E/G ratio of 2.52 and a beta of 0.85.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.